Expert Review of Anticancer Therapy最新文献_第10页

Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy. FGFR和IDH抑制剂用于胆管癌治疗的进展。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-03-01 DOI: 10.1080/14737140.2023.2176846

Zachary J Brown, Samantha M Ruff, Timothy M Pawlik

{"title":"Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.","authors":"Zachary J Brown, Samantha M Ruff, Timothy M Pawlik","doi":"10.1080/14737140.2023.2176846","DOIUrl":"https://doi.org/10.1080/14737140.2023.2176846","url":null,"abstract":"Introduction: Cholangiocarcinoma (CCA) is an uncommon malignancy originating from epithelial cells of the biliary tract. Regardless of the site of origin within the biliary tree, CCAs are generally aggressive with a poor survival. Surgical resection remains the only chance for cure, yet a majority of patients are not surgical candidates at presentation. Unfortunately, systemic therapies are often ineffective and complicated by side effects. As such, more effective targeted therapies are required in order to improve survival.Area covered: Genetic analysis of CCA has allowed for a better understanding of the genomic landscape of CCA. Isocitrate dehydrogenase (IDH) and fibroblast growth factor receptor (FGFR) mutations have emerged as the most promising molecular targets for CCA. Inhibitors of IDH and FGFR have proven to have therapeutic benefit with an acceptable safety profile. However, patients often develop resistance rendering the therapy ineffective.Expert opinion: Understanding the molecular pathways of IDH and FGFR may lead to a better understanding of the mechanisms of resistance. Thus, novel therapies may be developed to improve the efficacy of these therapies. Developing novel biomarkers may improve patient selection and further enhance effectiveness of targeted therapies.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 3","pages":"257-264"},"PeriodicalIF":3.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9525824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Utilizing clinical, pathological and radiological information to guide postoperative radiotherapy in prostate cancer. 利用临床、病理及影像学资料指导前列腺癌术后放疗。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-03-01 DOI: 10.1080/14737140.2023.2181795

Jerusha Padayachee, Simone Chaudhary, Brian Shim, Jonathan So, Remy Lim, Srinivas Raman

{"title":"Utilizing clinical, pathological and radiological information to guide postoperative radiotherapy in prostate cancer.","authors":"Jerusha Padayachee, Simone Chaudhary, Brian Shim, Jonathan So, Remy Lim, Srinivas Raman","doi":"10.1080/14737140.2023.2181795","DOIUrl":"https://doi.org/10.1080/14737140.2023.2181795","url":null,"abstract":"Introduction: A detectable and rising PSA following radical prostatectomy is indicative of recurrent prostate cancer. Salvage radiotherapy (SRT) with/without androgen deprivation therapy represents the main treatment option for these patients and has been historically associated with a biochemical control rate of ~70%. To determine the optimal timing, diagnostic workup, radiotherapy dosefractionation, treatment volume, and use of systemic therapy, several informative studies have been conducted in the last decade.Areas covered: This review examines the recent evidence to guide radiotherapy decision making in the SRT setting. Key topics include adjuvant vs salvage RT, utilization of molecular imaging and genomic classifiers, length of androgen deprivation therapy, inclusion of elective pelvic volume, and emerging role for hypofractionation.Expert opinion: Recently reported trials, conducted in an era prior to the routine use of molecular imaging and genomic classifiers, have been pivotal in establishing the current standard of care for SRT in prostate cancer. However, decisions about radiation treatment and systemic therapy may be tailored based on available prognostic and predictive biomarkers. Data from contemporary clinical trials are awaited to define and establish individualized, biomarker-driven approaches for SRT.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 3","pages":"293-305"},"PeriodicalIF":3.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9227056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breakthrough cancer pain in the radiotherapy setting: a systematic and critical review. 放射治疗中突破性的癌症疼痛:一个系统和关键的回顾。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-03-01 DOI: 10.1080/14737140.2023.2182773

Sebastiano Mercadante

引用次数: 1

Safety and efficacy of Elotuzumab combination therapy for patients with multiple myeloma: A systematic review and meta-analysis. Elotuzumab联合治疗多发性骨髓瘤患者的安全性和有效性:一项系统评价和荟萃分析。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-03-01 DOI: 10.1080/14737140.2023.2169139

Maryam Noori, Farimah Fayyaz, Nima Rezaei

{"title":"Safety and efficacy of Elotuzumab combination therapy for patients with multiple myeloma: A systematic review and meta-analysis.","authors":"Maryam Noori, Farimah Fayyaz, Nima Rezaei","doi":"10.1080/14737140.2023.2169139","DOIUrl":"https://doi.org/10.1080/14737140.2023.2169139","url":null,"abstract":"Objective: We evaluate the efficacy and safety of Elotuzumab, an immunostimulatory monoclonal antibody, in combination with concomitant treatment regimens for multiple myeloma (MM) patients.Research design and methods: PubMed, Scopus, Web of Science, and EMBASE databases were searched systematically up to 2 August 2022.Results: Five randomized control trials with a total of 1,763 participants were included. Elotuzumab combination therapy improved PFS and OS by 14% (hazard ratio [HR] 0.86) and 20% (HR 0.80), respectively, relative to the non-Elotuzumab regimen. Adding Elotuzumab to Lenalidomide plus Dexamethasone regimen (HR 0.82) or Pomalidomide plus Dexamethasone regimen (HR 0.54) were considered to improve the PFS. Meanwhile, the risk of disease progression was only reduced for patients with relapsed/refractory MM (HR 0.70) but not for newly diagnosed/untreated MM (HR 0.93). Finally, the risk of serious adverse events (RR 1.12) and the risk of infection (RR 1.09) and cardiac disorders (RR 1.32) were higher for the experimental group compared to the control group.Conclusions: Our findings showed that Elotuzumab combination therapy prolonged OS and PFS compared to non-Elotuzumab treatments in patients with MM. However, further investigations are required to establish the most effective combination of the Elotuzumab regimen.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 3","pages":"327-338"},"PeriodicalIF":3.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9525329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of the nodal yield in oral squamous cell carcinoma: a systematic review and meta-analysis. 口腔鳞状细胞癌淋巴结的预后价值:一项系统回顾和荟萃分析。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-03-01 DOI: 10.1080/14737140.2023.2168648

Jiajia Li, Yubo Xu, Jie Zhang, Shaohai Wang, Xiaoyu Wang, Huayan Guo, Guojun Miao

{"title":"Prognostic value of the nodal yield in oral squamous cell carcinoma: a systematic review and meta-analysis.","authors":"Jiajia Li, Yubo Xu, Jie Zhang, Shaohai Wang, Xiaoyu Wang, Huayan Guo, Guojun Miao","doi":"10.1080/14737140.2023.2168648","DOIUrl":"https://doi.org/10.1080/14737140.2023.2168648","url":null,"abstract":"Objectives: To systematically evaluate the prognostic value of the nodal yield in oral squamous cell carcinoma by meta-analysis.Methods: The meta-analysis was adherence to PRISMA. We searched MEDLINE, Embase, and Cochrane for studies published up to 20 April 2022. We collected evidences from observational studies regarding nodal yield in oral squamous cell carcinoma, and investigated its prognostic value by the routine methods of meta-analysis.Results: From seven studies, there was no significant impact of the lymph node yield on overall survival among patients with oral squamous cell carcinoma cases and <18 lymph nodes (hazard ratio (HR) = 1.019, 95% confidence interval (CI) = 0.786-1.320, p = 0.887), with significant heterogeneity (I2 = 80%). The pooled result indicated that a > 18-lymph node yield was a favorable prognostic factor (HR = 0.786, 95%CI = 0.646-0.956, p = 0.016; I2 = 39%). The lymph node yield was not associated with disease-specific survival (HR = 1.594, 95%CI = 0.996-2.552, p = 0.052; I2 = 81%) or disease-free survival (HR = 1.508, 95%CI = 0.924-2.460, p = 0.100; I2 = 41%).Conclusion: A lymph node yield of ≥18 lymph nodes might be a favorable prognostic factor for the overall survival of patients with oral squamous cell carcinoma.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 3","pages":"339-345"},"PeriodicalIF":3.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9174141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma. Lisocabtagene maraleucel治疗复发或难治性大b细胞非霍奇金淋巴瘤。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-02-01 DOI: 10.1080/14737140.2023.2171397

Razan Mohty, Yenny Moreno Vanegas, Julio C Chavez, Mohamed A Kharfan-Dabaja

{"title":"Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma.","authors":"Razan Mohty, Yenny Moreno Vanegas, Julio C Chavez, Mohamed A Kharfan-Dabaja","doi":"10.1080/14737140.2023.2171397","DOIUrl":"https://doi.org/10.1080/14737140.2023.2171397","url":null,"abstract":"Introduction: Chimeric antigen receptor T (CAR T) cell therapy epitomizes the success of T cell engineering. Today, it is an integral component of the treatment algorithm for various types of B-cell non-Hodgkin lymphoma (NHL). Large B-cell lymphoma (LBCL) is the most common subtype of NHL accounting for 30-35% of cases. A lack of response to second-line therapy portends a poor prognosis as only 7-15% of patients attain complete remission (CR) with subsequent conventional chemoimmunotherapy.Areas covered: Lisocabtagene maraleucel (liso-cel) is an autologous CD-19 directed CAR T-cell product with a 4-1BB co-stimulatory domain administered as a sequential infusion of 2 separately manufactured components: CD8+ and CD4+ CAR T-cells in equal doses. Liso-cel showed an impressive objective response rate of 73% (CR = 53%) in patients who had received a median of 3 prior therapies. Median time-to-first CR or partial response (PR) was 1 month.Expert opinion: When evaluated in the second line setting in LBCL, liso-cel demonstrated superior event-free survival (EFS) versus standard of care. While acknowledging that choice of a particular CAR T-cell is based chiefly on familiarity of the treating physician with a specific product, liso-cel definitely represents an important addition to the treatment armamentarium of R/R LBCL whether in the second-line setting or beyond.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 2","pages":"121-126"},"PeriodicalIF":3.3,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9109654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy with chemotherapy and anti-angiogenic therapy for EGFR mutated NSCLC: challenging the dogma. 免疫疗法联合化疗和抗血管生成治疗EGFR突变的NSCLC:挑战教条。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-02-01 DOI: 10.1080/14737140.2023.2152795

Aaron C Tan, Keigo Kobayashi, Stephanie P L Saw, Daniel S W Tan, Darren Wan-Teck Lim

引用次数: 0

Balancing efficacy with long-term side-effects: can we safely de-escalate therapy for germ cell tumors? 平衡疗效与长期副作用:我们能否安全地降低生殖细胞肿瘤的治疗级别?

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-02-01 DOI: 10.1080/14737140.2023.2162042

Jonathan Shamash, Kenrick Ng

引用次数: 1

Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials. 抗血管生成药物联合放化疗治疗局部晚期宫颈癌的疗效和安全性:一项随机对照试验的荟萃分析

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-02-01 DOI: 10.1080/14737140.2023.2157816

Yihua Zou, Yue Si, Fangqin Tong, Meng Guan, Chun Bi, Xia Wang

{"title":"Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials.","authors":"Yihua Zou, Yue Si, Fangqin Tong, Meng Guan, Chun Bi, Xia Wang","doi":"10.1080/14737140.2023.2157816","DOIUrl":"https://doi.org/10.1080/14737140.2023.2157816","url":null,"abstract":"Background: Neovascularization is an important factor causing radiotherapy resistance, tumor growth, and metastasis. It may provides a new direction for treatment of cervical cancer.Objective and methods: The main objective is to systematically evaluate the clinical efficacy and safety of antiangiogenic therapy combined with CCRT in the treatment of cervical cancer. We searched major Chinese and English databases to collect relevant studies from the database establishment up to April 2022. The experimental group of the studies included used CCRT combined with anti-angiogenic therapy, while another used only CCRT. We used the 'Cochrane Collaboration's tool' to assess risk of bias and RevMan 5.4 to conduct analysis.Results: Twelve studies with 793 patients were included. Use clinical efficiency and adverse reactions as effect indicators. It showed that the combination can improve the ORR (OR = 3.52, P < 0.00001), CR(OR = 2.46, P < 0.00001), DCR (OR = 2.64, P= 0.005), and OS(HR = 0.56, P = 0.03). But it increases the risk of neutropenia (OR = 1.86, P = 0.004) and hypertension (OR = 5.57, P = 0.003).Conclusions: Combined therapy can improve the clinical efficacy of cervical cancer, but the safety needs to be considered.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 2","pages":"217-227"},"PeriodicalIF":3.3,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9110722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance. 基于免疫疗法的egfr突变晚期非小细胞肺癌患者在EGFR-TKI耐药后的治疗前景看好

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-02-01 DOI: 10.1080/14737140.2023.2170879

Jianghua Ding, Xinjing Ding, Zhaohui Leng

{"title":"Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance.","authors":"Jianghua Ding, Xinjing Ding, Zhaohui Leng","doi":"10.1080/14737140.2023.2170879","DOIUrl":"https://doi.org/10.1080/14737140.2023.2170879","url":null,"abstract":"Introduction: Traditionally, epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) has been regarded as a cold tumor based on the immunosuppressive tumor immune microenvironment (TIME). However, recent studies have found that EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment could shift host immunity from immunosuppressive to immunosupportive TIME, which has renewed hopes of immunotherapy.Areas covered: In this review, we highlight five main immunotherapy-based therapies for patients after EGFR-TKI failure, including safety and efficacy data from prospective and retrospective clinical studies.Expert opinion: The efficacy of immunotherapy alone is extremely limited. Immunotherapy plus chemotherapy show an ORR of 29.5%-59.3% and an mPFS of about 7 months. There is still scarce evidence for immunotherapy plus antiangiogenesis therapy. A combination of immunotherapy with EGFR-TKIs exhibits higher treatment-related adverse events and lower clinical outcomes compared to EGFR-TKI alone. Importantly, immunotherapy plus antiangiogenesis and chemotherapy achieves an mPFS of 6.9-10.2 months. In general, the strategy of combining immunotherapy with chemotherapy and/or an antiangiogenic drug is a novel and promising method for treating advanced NSCLC after EGFR-TKI failure. Therefore, the dominant population of EGFR-TKI resistant patients were characterized by EGFR uncommon mutation, EGFR L858R mutation, PD-L1 ≥ 50%, prior antiangiogenic drugs, and negative T790 M mutation for immunotherapy-based therapy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 2","pages":"187-198"},"PeriodicalIF":3.3,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9111404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2